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ABSTRACT
Unrecognized depression during adolescence can result in adult suicidal behaviour. The aim of
this study was to identify, replicate and characterize DNA methylation (DNAm) shifts in depression
aetiology, using a longitudinal, multi-tissue (blood and brain) and multi-layered (genetics, epige-
netics, transcriptomics) approach. We measured genome-wide blood DNAm data at baseline and
one-year follow-up, and imputed genetic variants, in 59 healthy adolescents comprising the
discovery cohort. Depression and suicidal symptoms were determined using the Development
and Well-Being Assessment (DAWBA) depression band, Montgomery-Åsberg Depression Rating
Scale-Self (MADRS-S) and SUicide Assessment Scale (SUAS). DNAm levels at follow-up were
regressed against depression scores, adjusting for sex, age and the DNAm residuals at baseline.
Higher methylation levels of 5% and 13% at cg24627299 within the MET gene were associated
with higher depression scores (praw<1e-4) and susceptibility for suicidal symptoms (padj.<0.005).
The nearby rs39748 was discovered to be a methylation and expression quantitative trait locus in
blood cells. mRNA levels of hepatocyte growth factor (HGF) expression, known to strongly interact
with MET, were inversely associated with methylation levels at cg24627299, in an independent
cohort of 1180 CD14+ samples. In an open-access dataset of brain tissue, lower methylation at
cg24627299 was found in 45 adults diagnosed with major depressive disorder compared with
matched controls (padj.<0.05). Furthermore, lower MET expression was identified in the hippocam-
pus of depressed individuals compared with controls in a fourth, independent cohort. Our
findings reveal methylation changes at MET in the pathology of depression, possibly involved in
downregulation of HGF/c-MET signalling the hippocampal region.
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Introduction
Depression in adolescents is a prediction marker for
suicidal behaviour in adulthood [1,2]. Approximately
one million people die by committing suicide every
year worldwide [3] and over 90% of them have a
diagnosable mood disorder including depression [4].
Moreover, adolescent-onset recurrent major depres-
sion disorder (MDD) is linked tomore severe psycho-
social impairment during adulthood compared with
adult-onset recurrent MDD [5]. The development of
depression is the result of an interaction between
environmental and genetic risk factors [6].
Emerging evidence suggests that psychosocial
stressors affect epigenetic patterns in blood and
brain tissues [7–9], which can lead to long-term
gene expression changes [10]. The best-character-
ized epigenetic mark, DNA methylation (DNAm),
reflects the interplay between environmental stress
and genetic contribution to depression over the
lifespan [11,12]. DNAm involve the addition of a
methyl group to DNA, typically at a cytosine
nucleotide adjacent to a guanine (CpG). Studies
have investigated DNAm of candidate genes in
depression aetiology, such as BDNF, SLC6A4 and
NR3C1 [13,14]. Importantly, DNAm patterns are
notoriously tissue-specific [15], with moderate
correlations between DNAm variation in blood
and post-mortem brain tissue [16–18]. To date,
epigenome-wide association studies (EWAS) of
depression mainly focused on the adult popula-
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tion, using whole blood [19–23], brain [24,25] or
saliva samples [26]. These studies identified differ-
entially methylated CpGs within genes such as
ZBTB20, WDR26 and GHSR and differentially
methylated regions in the GRIK2, BEGAIN and
PRIMA1 genes. Differences in tissue sources, eth-
nicity, co-morbidity diagnoses and medication his-
tory, may partly explain why these studies failed to
find common CpGs robustly associated with
depression. Therefore, using both whole blood
and brain tissues would allow gaining more insight
into the regulatory mechanisms of depression.
Adolescent neurodevelopment is modulated by
environmental signals [27], yet without being
affected by a large variety of abundant psychiatric
comorbidities and medication usage. Moreover,
analysing DNA signatures at early stages reduces
the noise created by stochastic DNAm changes
that happen with advancing age [28]. Only two
studies reported methylome-wide findings asso-
ciated with depression in adolescents [29,30].
One study that identified inverse association
between methylation at MIR4646 and gene expres-
sion was underpowered (n = 11 adults). Another
study reported increased DNAm at STK32C in
blood of 18 pairs of monozygotic adolescent
twins discordant for depression, and replicated
the findings in cerebellar tissue, but did not inves-
tigate the downstream effects on RNA expression
[30]. Moreover, both studies were cross-sectional,
while a longitudinal approach tracks changes in
depressive symptoms over time and identifies
DNA methylation shifts in a more controlled
environment [31].
Shifts in epigenetic patterns may be an early
mechanism at play in depression and thus, this
work aims to uncover longitudinal epigenetic pat-
terns in depression development. We used a long-
itudinal epigenome-wide approach to identify blood
DNAm changes associated with changes in depres-
sion in otherwise healthy adolescents.We then tested
whether these associations could be correlated with
nearby SNP presence by conducting a mQTL analy-
sis. In addition, we tested for replication of the asso-
ciations between DNAm and depression in an
independent dataset of brain tissue. We further
investigated the functional relevance of these depres-
sion-associated DNAm signatures by integrating
them with gene expression in a third dataset.
Importantly, we showed in a fourth cohort that
genes annotated to these DNAm signatures were
differentially expressed in the hippocampus of
depressed individuals. Using four independent
cohorts consisting of blood and brain samples and
a statistical framework for analysing longitudinal
epigenetic data, we uncovered a broad epigenetic-
genetic network in the pathology of depression. Our
results are summarized in Figure 1.
Results
Demographic and clinical characteristics of
discovery and replication cohorts
The discovery cohort consisted of 59 Caucasian
adolescents who had available imputed genetic
data, recorded psychiatric phenotype and blood
DNAm levels at both baseline and 1-year follow-
up. Depression scores were assessed by the stan-
dardized Development and Well-Being
Assessment (DAWBA) depression band at base-
line and follow-up, and by the Montgomery-
Åsberg Depression Rating Scale-Self report
(MADRS-S) at follow-up only. Adolescents
defined as cases and controls based on the
DAWBA and MADRS-S scores at follow-up did
not differ in age, sex distribution or body mass
index (BMI). While the majority of controls had
low depression scores at both baseline and fol-
low-up, 19 adolescents showed an increased risk
for depression from baseline to follow-up
(Table 1).
The replication cohort comprised of 45 male
and female Caucasians (Table 2), with DNAm
profiling in brain tissue. Individuals diagnosed
with MDD and controls did not differ in age or
sex distribution.
Differential methylation associated with
depression risk, suicidal behaviour and mRNA
expression in the blood
In the discovery cohort, we aimed to identify epi-
genome-wide associations between changes in
depression risk and changes in methylation levels,
focusing on CpGs located in promoter regions
(from baseline to 1-year follow-up).
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Depression risk at follow-up (i.e. control/case)
was used as the outcome variable and corrected for
methylation residuals at baseline, sex and age. A
total of 5,785 CpG sites were nominally
(praw<0.05) associated with changes in depression
risk from baseline to follow-up, 53% of which were
hypomethylated in cases. However, none of these
sites remained significant after adjustment for
multiple testing (Figure 2), so a stricter nominal
threshold of p = 10−4 [19,20] was chosen. Nine
CpG sites were associated with depression risk at
praw < 10
−4 (Table 3). The calculated inflation
factor of our epigenome-wide analysis was λ =
0.89, suggesting that there was no overestimation
of the level of statistical significance. The largest
methylation difference was detected at cg24627299
within the hepatocyte growth factor receptor
(MET) gene, DNAm being 5% higher in cases
(0.54 ± 0.03) than in controls (0.49 ± 0.04)
(Figure 3). Methylation levels at this site were
measured by pyrosequencing in a larger sample
of 203 individuals at both baseline and follow-up.
The normally distributed methylation values at
follow-up were regressed against the dichotomous
depressive phenotype variable, including the
methylation residuals at baseline, age, sex and
technical covariates. A clear tendency (two-sided
p = 0.076) of increased methylation at cg24627299
in ‘cases’ compared to methylation levels of their
healthy counterparts was observed.
We also investigated a possible association
between the continuous scores for suicidal symp-
toms in SUAS and the previously identified nine
CpGs. Four of the nine methylation sites asso-
ciated with depression risk were also associated
with suicide (Table 3). Similar to the observation
made in relation to depression scores, methylation
levels were higher for increased suicide symptoms
at three out of four CpG sites. The largest effect
size of methylation shifts was seen at the afore-
mentioned cg24627299 within the MET gene.
The HGF gene is located in the same chro-
mosomal region (7q21-11) as its receptor the c-
MET tyrosine kinase (7q.31) encoded by the
MET gene. Given the interaction of c-MET and
HGF and their close chromosomal localization,
methylation levels at the MET gene were inves-
tigated in relation to both MET and HGF
expression levels using a methylation-expression
cohort (Figure 1). A suggestive inverse associa-
tion between blood methylation levels at
cg24627299 and mRNA expression of HGF
(transcript ID: ILMN_1801586, praw = 0.046,
estimate = −0.050) was identified. No association
at this CpG site with expression levels of MET
gene was identified.
Discovery cohort at screening 
(n=74)
Discovery cohort at 1-year follow-up
(n=203)
Longitudinal DNAm on 
depression*
159 controls vs 44 cases
mQTL analyses (n=72)
Longitudinal DNAm on 
depression*
36 controls vs 23 cases
Methylation at cg24627299 was 
associated with depression at p = 
0.076
Nine differentially methylated CpGs
for depression at unadjusted p < 1e-4
450K, EPIC PyrosequecingImputed SNPs
Methylation-expression cohort 
(n = 1,180)
Cross-sectional DNAm
analysis
Expression mRNA of
MET and HGF
DNAm shifts within MET were 
associated with HGF mRNA levels
Replication cohort (n = 45)
Cross-sectional DNAm
analyses at nine CpGs
22 MDD-diagnosed vs 
23 matched controls
MDD-associated DNAm shifts at 
cg24627299 (MET)
Expression cohort (n = 30)
Altered MET and HGF mRNAs in 
hippocampus of depressed 
individuals
mRNA data of MET
and HGF
15 MDD-diagnosed vs 
15 matched controls
Blood
Brain
Figure 1. Study design for methylation and expression association with depression using four cohorts. Blood associations between
DNA methylation and depression risk, genotype and mRNA expression were investigated using two independent cohorts, i.e. the
discovery cohort and methylation-expression cohort. In brain, methylation and mRNA levels were separately analysed in relation to
MDD in two independent cohorts. * Individuals with depression DAWBA band risk scores below 15% and MADRS-S scores <9 were
defined as ‘Controls’, while individuals with depression DAWBA level bands 3 (≈ 15%), 4 (≈ 50%) or 5 (>70%) and MADRS-S scores
≥9 were assigned to the ‘Cases’ category. SNPs: single nucleotide polymorphisms; MDD: major depression disease.
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Lower methylation at cg24627299 and mRNA
levels of MET and HGF are associated with MDD
in the brain
Methylation levels at the nine CpG sites (praw < 10
−4)
associated with depression in the blood discovery
cohort were investigated in a replication cohort con-
sisting of post-mortem cortical tissues of MDD-diag-
nosed and matched-controls (n = 45). Methylation
data were available for both neuronal and glial cells.
Methylation at cg24627299 (MET) adjusted for age
and sex, was associated with depression in neurons
(FDR-adjusted p = 0.0437, absolute difference = 2.6%)
(Figure 4), yet the significance did not survive after
FDR adjustment in the glial cells (Table 4). In contrast
to the findings in blood, methylation levels were lower
in the brain from individuals diagnosed with MDD
compared to controls.
To investigate HGF-MET signalling dysregula-
tion in depression, we contrasted MET and HGF
mRNA expression levels in hippocampus region of
depressed and healthy adults in a fourth indepen-
dent cohort (see Methods). By alternative splicing,
the genes give rise to several transcript sequences.
The HEEBO array covers five oligo sequences of
MET and HGF, associated with two accession
numbers, i.e. NM_000245 and NM_001010932.
Binomial tests were run separately for the dentate
gyrus and CA1 sub-regions of hippocampus. More
than 50% of the average expression values were
higher in the matched controls compared to the
MDD-diagnosed individuals (p < 0.05), indicating
lower expression levels of MET and HGF in the
adult-depressed hippocampus (Supplementary
Table 1).
Methylation levels at cg24627299 showed
functional relevance in the brain tissue but not
whole blood
Using the GTEx online database, MET gene was
found highly expressed in the cortex, frontal
cortex and hippocampus, contrasting with low
expression in whole blood (Figure 6(a)). The
HGF gene was highly expressed in whole
blood, frontal cortex, cortex and BA24 region
(Figure 6(a)). Moreover, exploration of chro-
matin states of this locus revealed that
cg24627299 is located within active chromatin
regions (i.e. TSS or enhancer) in all brain tis-
sues except the anterior caudate and substantia
nigra. In contrast, cg24627299 was located in a
region repressed by PolyComb proteins in
PBMCs (Figure 6(b)). Furthermore, based on
Table 1. Characteristics of the adolescents from the discovery
cohort at follow-up.
Controls (n =
36)
Cases (n =
23)
p-
value**
Male: Female 7 (19.4):29
(80.6)
3 (13.1):20
(86.9)
0.77
Age (years) 18.6 ± 0.72 18.6 ± 0.87 0.46
Body Mass Index (kg/m2) 22.68 ± 3.08 23.72 ± 4.13 0.30
SUAS 9.38 ± 4.49 25.7 ± 9.26 1.20e-
08
DAWBA level bands*
General band 4 (11.1) 100 (100) 3.68e-9
Panic disorder 0 (0) 1 (4.3) 0.0037
Posttraumatic disorder 0 (0) 5 (21.7) 0.0084
Separation anxiety disorder 2 (5.6) 2 (8.7) 0.035
Social phobia 0 (0) 8 (34.8) 0.0017
Obsessive-compulsive
disorder
0 (0) 2 (8.7) 0.00045
Conduct disorder 0 (0) 3 (13.0) 0.22
Specific phobia 1 (2.8) 5 (21.7) 0.11
DAWBA level bands at
baseline*
Depression 3 (8.3) 4 (17.4) 0.19
General band 7 (19.4) 13 (56.5) 0.028
Panic disorder 0 (0) 2 (8.7) 0.25
Posttraumatic disorder 1 (2.7) 0 (0) 0.32
Separation anxiety disorder 1 (2.7) 0 (0) 0.064
Social phobia 1 (2.7) 5 (21.7) 0.0087
Obsessive-compulsive
disorder
1 (2.7) 0 (0) 0.37
Conduct disorder 1 (2.7) 1 (4.3) 0.65
Specific phobia 0 (0) 4 (17.4) 0.071
Continuous variables are shown as mean ± standard deviation or
number (percentage)
*All listed DAWBA bands refer to ‘cases’ (defined by DAWBA bands = 3,
4 or 5) of e.g. general band, depression, panic disorder.
**Two-tailed Student’s t-test for continuous variables and Chi-square
test for categorical variables. (Likelihood ratio)
Individuals with depression DAWBA band risk scores <15% and
MADRS-S scores <9 were defined as controls; individuals with depres-
sion DAWBA level bands 3 (≈ 15%), 4 (≈ 50%) or 5 (>70%) and
MADRS-S scores ≥9, were defined as cases.
Abbreviations: DAWBA, Development and Well-Being Assessment;
SUAS, SUicide Assessment Scale; MADRS-S, Montgomery-Åsberg
Depression Rating Scale-Self report
Table 2. Characteristics of individuals in the replication cohort.
MDD (n = 22) Controls (n = 23) p-value*
Male: Female 12 (54.5):10 (45.5) 12 (52.2):11(47.8) 1
Age (years) 33.6 ± 16.4 33.4 ± 16.2 0.95
Continuous variables are shown as mean ± standard deviation or
number. (percentage)
*Two-tailed analysis tests the difference between the ‘MDD’ and
‘Controls’ groups using the Student’s t-test for continuous variables
and the Chi-square test for categorical variables. (Likelihood ratio)
MDD: major depression disorder.
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the online BECon tool resource of comparing
methylation levels in whole blood and three
brain regions, blood methylation levels at
cg24627299 inversely associated with BA10,
BA20 and BA7 methylation levels, supporting
an opposite pattern of methylation observed
originally in whole blood and brain.
Genotypes at rs39748 are associated with
differential methylation at cg24627299 in whole
blood
Taking into account the influence of genetic
variants on both methylation [32,33] and gene
expression [34], we performed mQTL and eQTL
analyses of SNPs within 100 kbp (up- and down-
stream) of cg24627299 using 74 individuals from
the discovery cohort that had both imputed
SNPs and DNA methylation data at follow-up.
Using the hg19 version of the UCSC genome
browser, we identified 39 genetic variants within
100 kbp of cg24627299. Twenty independent
genetic variants were not in LD (r2 < 0.8)
(Figure 5) and had MAF > 0.3 in the discovery
cohort. Based on an additive model, we identi-
fied one genetic variant (rs39748), located in
intron 1 of MET and ~16 kpb downstream of
cg24627299, that was nominally associated with
Figure 2. Manhattan plot of the longitudinal epigenome-wide association of depressive-transformed variable in whole-blood
samples of 59 adolescents. The depressive-transformed variable was calculated based on depression DAWBA band risk scores and
MADRS-S scores. The blue line represents the significance level at p = 10−4.
Table 3. List of differentially methylated CpG sites in longitudinal analyses.
Depression phenotype Suicide symtomps
Probe Chr Positiona
Distance to closest
TSS
[bp]
Closest
gene
Raw p-
value Estimate
Methylation
Difference %
Raw p-
value
FDR-adjusted p-
values Estimate
cg23415434 2 131,515,339 1768 ARHGEF4 7.61e-06 −0.27 3.5 0.048 0.1 −0.0077
cg23897356 6 30,795,992 −143 TUBB 9.72e-06 0.17 <1 0.00051 0.0034 0.0065
cg13518442 15 56,146,171 −758 ALDH1A2 1.93e-05 −0.14 2 0.061 0.1 -
cg18081313 12 130,944,145 −1086 ULK1 6.55e-05 0.18 <1 0.094 0.12 -
cg09312254 12 110,935,362 10 AX747754 7.03e-05 0.11 <1 0.083 0.12 -
cg24627299 7 116,098,732 −962 MET 8.40e-05 0.27 5 0.00077 0.0034 0.012
cg03920003 1 152,848,631 −1283 ADAR 8.75e-05 0.50 3 0.11 0.13 -
cg02935298 22 41,366,678 −127 ATP5L2 8.93e-05 −0.16 <1 0.13 0.13 -
cg02249030 6 100,068,675 1298 USP45 9.75e-05 0.13 <1 0.0038 0.011 0.0049
Position was according to Human Reference Genome build 37 (hg19).
P-values < 0.05 are written in bold.
The depression phenotype was calculated based on depression DAWBA band risk scores and MADRS-S scores. Participants with depression DAWBA
band values ≥3 and MADRS-S scores ≥9 were categorized as ‘cases’, while participants with depression band values <3 and MADRS scores <9
were categorized as ‘controls’. Susceptibility for suicidal symptoms was measured with the SUAS questionnaire.
Chr:, chromosome; TSS: transcription start site; bp: base pair; DAWBA: standardized Development and Well-Being Assessment; MADRS-S:
Montgomery-Åsberg Depression Rating Scale-Self; SUAS: Suicide Assessment Scale.
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methylation levels at cg24627299 (p = 0.045,
effect size (CC: CG) = 1% (CC: GG) =
−2.8%)), after adjusting for age and sex.
Methylation levels at cg24627299 at rs39748
genotypes were 0.51 ± 0.05 at CC, 0.52 ± 0.04
at CG and 0.48 ± 0.04 at GG. In the discovery
cohort, the MAF at rs39748 was 0.36, similar to
the whole-population frequency of 0.34. Notably,
this variant was also associated with MET
mRNA expression, and the highest effect sizes
were seen in brain regions (Table 5).
Discussion
Here, we conducted a comprehensive analysis of
epigenetic, transcriptomic and genetic information
in four independent cohorts and two tissues,
including longitudinal EWAS, to uncover epige-
netic shifts associated with high risk for depres-
sion. Higher methylation at cg24627299 within the
MET gene was associated with a high risk for
depression and susceptibility for suicidal beha-
viour in blood, while lower methylation at
cg24627299 was observed in cortical tissue of
depressed adults. Importantly, methylation shifts
at this site were inversely associated with expres-
sion levels of the MET ligand HGF in blood, indi-
cating a possible functional relationship between
Figure 3. Blood DNAm levels (β-values) at cg24627299 within
the MET gene for adolescents defined as ‘controls’ and ‘cases’.
Individuals with depression DAWBA band risk scores below 15%
and MADRS-S scores <9 were defined as ‘Controls’, while indivi-
duals with depression DAWBA level bands 3 (≈ 15%), 4 (≈ 50%)
or 5 (>70%) and MADRS-S scores ≥9 were assigned to the ‘Cases’
category.
Figure 4. Methylation levels at cg24627299 (MET) in brain samples of MDD-diagnosed individuals and controls.
Table 4. Differentially methylated CpG sites in the brain.
Probe
Raw p-value
[nuclei]
FDR adjusted p-value
[nuclei]
Methylation Difference %
[nuclei]
Raw p-value
[glia]
FDR adjusted
p-value [glia]
Methylation Difference %
[glia]
cg02249030 0.71 0.80 0.51 0.78 0.78 0.11
cg02935298 0.64 0.80 0.32 0.17 0.38 0.91
cg03920003 0.80 0.80 0.38 0.09 0.38 1.7
cg09312254 0.32 0.80 0.23 0.70 0.78 0.081
cg13518442 0.76 0.80 0.16 0.77 0.78 0.36
cg18081313 0.54 0.80 0.72 0.42 0.63 1.3
cg23415434 0.66 0.80 0.33 0.12 0.38 2.8
cg23897356 0.062 0.28 0.35 0.23 0.41 0.21
cg24627299 0.0041 0.037 2.6 0.021 0.19 5.5
P-values were obtained using linear regression models, contrasting DNAm levels at the nine CpGs and the yes/no depression diagnosis, together
with covariates age and sex.
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methylation and expression. Interestingly, both
MET and HGF mRNA expressions were altered
in hippocampus of depressed individuals. These
findings highlight the interplay between methyla-
tion and expression of HGF, as well as on HGF/c-
MET signalling in the development of depression.
Our discovery of the changes in blood methyla-
tion levels in adolescents at risk for depression,
supported by the confirmatory approach in adult
brain samples, sheds light on depression aetiology.
MET encodes a tyrosine kinase receptor called c-
MET that has high affinity for HGF. Although c-
MET was shown to be regulated by a number of
transcription factors including p53 [35] and Daxx
[36], less is known about the role of DNA methy-
lation in regulating c-MET expression. Loss of
MET promoter methylation is involved in HGF-
dependent increase in tumorigenicity and meta-
static potential of hepatocellular carcinoma via
upregulation of c-Met and HGF expression [37].
Importantly, both MET and HGF are expressed in
the developing nervous system, especially in the
cerebral cortex [38,39], strengthening the impor-
tance of our replication in cortical tissue samples.
In the current study, altered gene expression of the
MET ligand HGF could be caused by methylation
changes at MET in the brain. This finding is sup-
ported by the locus harbouring the identified dif-
ferentially methylated CpG exerts a regulatory role
on transcription in the brain regions (Figure 6(b)),
supporting a functional link with MET and HGF
expression in the hippocampus. Our results sug-
gest that the interplay of these two molecules is
regulated at the gene expression level. Therefore,
altered activity of HGF/c-MET signalling due to
Figure 5. LD matrix of the 39 investigated genetic variants within the ±100 kbp of the differentially methylated CpG site
(cg24627299, MET gene).
Table 5. Distribution of the rs39748 eQTL contribution across
the tissues.
p-Value* NES Tissue
4.6e-18 −0.70 Brain – Caudate (basal ganglia)
5.9e-16 −0.71 Brain – Putamen (basal ganglia)
1.2e-10 −0.64 Brain – Hypothalamus
2.1e-10 0.24 Artery-Tibial
2.6e-10 −0.48 Brain – Nucleus accumbens (basal ganglia)
1.8e-9 0.34 Artery-Aorta
4.3e-9 −0.65 Brain – Substantia nigra
1.0e-8 −0.45 Brain – Cerebellum
1.8e-6 −0.58 Brain – Spinal cord (cervical c-1)
2.9e-6 −0.42 Brain – Cerebellar Hemisphere
1.9e-5 0.12 Lung
6.0e-5 0.16 Thyroid
*P-values NES and tissue regions were identified using quantitative trait
loci (eQTL) mapping, using the GTEx Consortium Abbreviations: NES:
normalized effect size.
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a)
b)
Figure 6. a) MET and HGF expression levels among different brain regions and whole blood. b) Genomic context of the most
significant CpG site associated with the depressive phenotype in the longitudinal analyses. Genomic positions of RefSeq genes are
displayed in the bottom part and indicated by arrows. The position of the significant CpG site is highlighted by black lines. Since
analyses were performed based on data obtained in blood, chromatin marks overlapping in brain and blood cells were investigated.
Chromatin states of eight tissues downloaded from the 37/hg19 WashU Epigenome Browser are illustrated. Each functional role of a
segment is indicated by a particular colour. BrainAC: brain anterior caudate; BrainCG: brain cingulate gyrus; BrainHIPPO: brain
hippocampus; BrainITL: brain inferior temporal lobe; BrainDPC: brain dorsolateral prefrontal cortex; BrainSN: brain substantia nigra;
BrainAG: brain angular gyrus; PBMC: peripheral blood mononuclear primary cells.
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methylation shifts may interfere with HGF-
mediated action on interneuron migration, dis-
rupting neuronal growth in the cortex [40].
DNAm levels at the identified CpG site within
MET gene in depression were associated with suici-
dal thoughts assessed by the SUAS questionnaire.
Previous studies investigating DNAm in relation to
both depression and suicidality found that decreased
anterior prefrontal GABRA1 levels in major depres-
sive suicide victims may be due to increased anterior
prefrontal GABRA1 gene promoter methylation
[41]. An EWAS in MDD suicide cases compared
with non-psychiatric, sudden death controls, found
hypomethylation at PSORS1C3 across both cortical
brain region, i.e. BA11 and BA25 [42]. DNAm levels
at the GRIK2 and BEGAIN genes involved in synap-
tic communication were associated with astrocyte
dysfunction in depression and suicide in the dorso-
lateral prefrontal cortex [24]. Lastly, among MDD
patients, altered DNAm levels at ELOVL5 were
found in suicide attempters when compared with
age- and sex-matched healthy volunteers [43].
Although we could not test the regulatory role of
genetic variants on MET and HGF mRNA expres-
sion levels, we found that the genetic variant rs39748,
located in intron 1 of the MET gene, was associated
with differential methylation at cg24627299 at fol-
low-up. During this time window (18–19 years), the
within-individual adjustment to environmental fac-
tors and its plasticity may be under genetic control.
Intriguingly, reduced protein levels of c-MET have
been associated with the C allele at theMET promo-
ter variant rs1858830 in post-mortem autistic brain
samples [44,45]. These findings indicate that changes
in DNA methylation may compensate and/or med-
iate the inter-individual genetic variation [46] and its
effect on gene expression.
Intriguingly, we found decreased levels of MET
and HGF in hippocampus of depressed individuals
compared with control hippocampi. A number of
studies have already examined depressive symp-
toms in relation to dysregulation of the hippocam-
pus [47]. Negative psychosocial factors induce
changes in hippocampal neural activity and synap-
tic plasticity [48] as well as in the prefrontal cor-
tical region [49]. Moreover, the disturbed activity
of the hippocampus can also be caused by a weak-
ening of excitatory synapses in, e.g. CA1, which
plays a critical role in the determination of affect
and reward [50]. Importantly, the hippocampus is
a prominent site for the expression of HGF and
MET in the developing and adult brain [51]
(Figure 6(a)). It has been demonstrated that HGF
and MET are clustered at the postsynaptic density
of excitatory synapses in CA1 and increased HGF
levels improve expression and clustering of excita-
tory synaptic proteins at sites along dendrites [52],
highlighting their importance for neuronal activ-
ity. Importantly, our results showed lower mRNA
levels of both HGF and MET in the hippocampus
of depressed adults. Consistently, a decreased HGF
protein level was reported in individuals with
obsessive-compulsive disorder, bipolar disorder
and depression [53–55]. Downregulation of HGF/
c-MET signalling reduces the axonal growth of
hippocampal neurons through deterioration of
the autocrine feedback loops [56], resulting in a
reduced arborization at excitatory synapses [57].
Processing of the input stimuli is thus altered and
an inadequate response is formulated [58], leading
to depressive symptoms (Figure 7). In addition,
alteration of HGF/c-MET at the excitatory
synapses in the CA1 region may disturb the con-
nection between the axons in the entorhinal cortex
with the distal dendrites of pyramidal cells, a path-
way required for long-term consolidation memory
[59]. Interestingly, as serotonin potentiates these
synapses, treatment of depression by conventional
agents such as selective serotonin reuptake inhibi-
tors results in restoration of the CA1 pyramidal
spine density and excitability [60–62].
Our findings on methylation changes at the
MET gene in whole blood were validated in an
independent cohort of prefrontal cortex samples,
and further extensively investigated in the brain
tissue. This is the first study which identifies dif-
ferential DNAm at the MET gene in depression.
This may be the result of the fact that our findings
derive from a longitudinal study, taking into
account the association of DNAm levels and
depression scores at two-time points, compared
to earlier EWASs that only used a cross-sectional
set-up. Whole blood is commonly used as surro-
gate for brain in DNAm studies due to accessibility
and its potential connection with neuropsychiatric
diseases through hormonal and immune regula-
tion [63]. However, given the tissue specificity of
DNAm, a cross-tissue analysis approach, using
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both brain and blood, may help in identifying
more relevant DNAm patterns in psychiatric
populations. Additionally, the EPIC array used in
our discovery analysis showed higher proportion
of correlated CpGs between blood and brain than
the previously used 450K array [64]. Using sepa-
rate cohorts, we discovered that higher methyla-
tion levels were associated with lower expression
levels at the HGF gene in whole blood in adoles-
cents at risk for depression and lower HGF expres-
sion levels in adult depressed hippocampus,
indicating that the association between DNAm
and expression levels may be translated to the
hippocampus. However, in the prefrontal brain
samples of depressed adults, we observed an oppo-
site direction of methylation patterns from blood,
i.e. lower DNAm at the CpG site. The finding is
not surprising, as DNAm dynamics are not only
tissue-specific, but may also significantly differ
across different regions of the brain [65]. Whole
blood can be assumed to reflect a partial summa-
tion of methylation changes at this CpG site occur-
ring in the brain. The observed opposite direction
of methylation patterns in blood and prefrontal
brain samples found in our study was also sup-
ported by an inverse correlation of methylation
levels at the identified CpG site between blood
and BA10 medial frontal gyrus region using the
BECon omics platform.
Our findings have to be evaluated in light of
their limitations. Firstly, due to the relatively small
sample size and effect sizes detected, no probe
reached the multiple-testing levels of significance.
As expected in longitudinal studies, methylation
differences are moderate (~5%), and, while the
directionality could be replicated using pyrose-
quencing in an extended cohort, significance
could not be reached, likely due to the 5%
Figure 7. Connections in the hippocampal formation. In the hippocampus, sensory information arrives from the cerebral association
neocortex via the entorhinal cortex, parahippocampal gyrus and/or perirhinal cortex. The hippocampal subfield CA1 sends axons to
both subcortical areas and the deep layers of the entorhinal cortex, either directly or through the subiculum. Processed information
is sent back from the hippocampal CA1 area to the cerebral association cortex through the same pathway. Higher methylation levels
at the promoter of MET may alter the autocrine mechanism of HGF/c-MET signalling necessary for promoting axonal growth at the
excitatory synapses of the CA1 hippocampal pyramidal neurons. The response to the environmental stimuli may therefore be altered,
leading to depressive symptoms.
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sensitivity limit of such a locus-specific method
[66]. In addition, our discovery and replication
cohorts were different in age (adolescents vs.
adults). This limitation was taken into considera-
tion by using statistical models adjusting for this
factor. A strength of our study is our longitudinal,
multi-tissue (blood and brain) and multi-layered
(genetics, epigenetics, transcriptomics) approach
affirming our findings from whole blood in the
prefrontal brain samples, indicating that the asso-
ciation may be of relevance for regulatory path-
ways in the brain. Importantly, adolescents were
free of medication with psychotropic effects, which
may affect methylation signatures. Lastly, our psy-
chiatric phenotype was assessed using two ques-
tionnaires, i.e. the MADRS-S and DAWBA
depression band, increasing the sensitivity of
analysis.
Conclusions
We present evidence that stable blood-based epi-
genetic changes are associated with risk for depres-
sion and susceptibility for suicidal behaviour in
adolescence. The complementary epigenetic and
genetic analyses may provide mechanistic support
for downregulation of the HGF and MET genes in
the hippocampus of depressed individuals. Our
findings suggest an important pathogenic role of
HGF/c-MET signalling in the pathophysiology of
depression, partly characterized by impaired neu-
ronal growth.
Methods
Study participants
Discovery dataset
The discovery cohort was a sample of a cohort of
786 unrelated Swedish adolescents aged 17–19,
recruited between 2012 and 2017 in Uppsala,
Sweden. This longitudinal study aims to investi-
gate potential psychiatric risk factors in youth and
followed up the subjects approximately 1 year after
study enrolment. Exclusion criteria at recruitment
included any severe cognitive impairment or med-
ication for psychiatric disorders. Height, age and
medication intake were self-reported. We mea-
sured body weight at the clinic and calculated for
body mass index (BMI). Methylation analysis at
baseline was available for 221 non-related adoles-
cents, analysed in two batches [29,32]. Out of 130
adolescents analysed in the first batch, a subset of
61 came at the follow-up and therefore had
extracted DNA available. From the second batch
of 91 adolescents, 11 were selected out of the 34
adolescents who answered positively to the follow-
up based on their very low/high psychiatric-related
scores at the DAWBA general band. In total, long-
itudinal DNA methylation analyses were applied
on a sample of 74 adolescents. The study was
approved by the Regional Ethics Committee in
Uppsala, corresponding to the Drnr 2011/446. All
participants volunteered to participate in the
study, and written informed consent has been
obtained.
Psychiatric phenotype of depression and disease
outcome
Participants were given a questionnaire at baseline
and at follow-up to assess both their baseline psy-
chiatric phenotype and any potential change in psy-
chiatric health over the one-year period. The
standardized DAWBA questionnaire assesses the
probability that an adolescent (aged 5–17 years) dis-
plays anxiety disorders, depression, post-traumatic
stress disorder, autism, separation anxiety disorder
and obsessive compulsive disorder [67]. The gener-
ated in silico scores include six band scores for risk, i.
e. 0 (<0.1%), 1 (≈ 0.5%), 2 (≈ 3%), 3 (≈ 15%), 4 (≈
50%) and 5 (>70%), based on Diagnostic and
Statistical Manual of mental disorders (DSM-IV)
and International Statistical Classification of
Diseases and Related Health Problems (ICD-10)
[68]. The DAWBA depression band consists of ques-
tions relating to the occurrence of depression symp-
toms in the last 4 months, such as e.g. the level of
sadness, irritability, sleep activity, wish to die and to
what extent general mood is affected. Individuals
with a score ≥3 were considered at high risk for
depression [69].
At follow-up, participants were given two
additional questionnaires, in order to provide
more support to the psychiatric-related pheno-
type. One of the most commonly used instru-
ments for the assessment of depressive
symptoms is the MADRS self-report
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questionnaire [70]. The MADRS-S comprises
nine questions assessing individuals’ mood, feel-
ings of unease, sleep, appetite, ability to concen-
trate, initiative, emotional involvement,
pessimism and zest for life. Items are rated on
a 7-point Likert scale (from 0 to 6) leading to a
total score ranging between 0 and 54. Study
participants were instructed to rate symptom
severity over the last three days. Individuals
with a score ≥9 were broadly considered depres-
sive [71]. The MADRS-S questionnaire was
available at follow-up only.
We further evaluated individual’s susceptibil-
ity for suicide or suicidal attempts with the
SUicide Assessment Scale (SUAS). This ques-
tionnaire assesses suicidal symptoms such as
despair, hostility, seclusion, loss of control,
somatization, death wishes and suicidal thoughts
and behaviour. The overall score ranges from 0
to 80.
Our study includes a population-based cohort
of adolescents; therefore, the prevalence of psy-
chiatric phenotypes is not that high, yet normal
for a population-based study [72,73]. In order to
increase the analysis power and sensitivity, both
the DAWBA depression band and MADRS-S
scores were transformed into a binary
depressed/not-depressed variable and used in
further analyses. Participants with depression
band values ≥3 and MADRS-S scores ≥9 were
categorized as ‘cases’, participants with depres-
sion band values <3 and MADRS-S scores <9
were categorized as ‘controls’. Subjects showing
depression band values of ≥3 and MADRS-S
scores <9 were assigned as ‘missing’ and omitted
from the analysis. A total of 59 individuals were
categorized as cases or controls, defining the
‘discovery dataset’.
Genome-wide DNA methylation profiling and
processing
Blood was collected at two-time points (base-
line and one-year follow-up). Baseline DNAm
profiles were assessed with the Illumina 450K
methylation Beadchip. Data preprocessing was
performed as described in [32,69]. It should be
noted that baseline methylomes were profiled
in two different time batches within a time
range of 1 year [32]. This time difference in
DNAm analyses at baseline will further be
referred to as ‘batch’ and taken into considera-
tion in the methylation analyses at baseline.
At follow-up, genomic DNA was extracted
from EDTA blood and 250 ng of DNA was
bisulphite-converted using the EZ DNA
Methylation Kit (Zymo Research Product,
Germany). DNA was eluted in 15μl buffer
according to the manufacturer’s protocol, evapo-
rated to a volume of <4 μl, and methylomes were
assessed with the Illumina Methylation EPIC
array. The results were analysed with
GenomeStudio 2011.1 from Illumina Inc. A
total of 74 samples had methylation data avail-
able for quality control procedures. The signal
intensities from the methylated and unmethy-
lated channels were normalized with the noob
procedure in R [74] and the DNA methylation
level, called beta value, was calculated by the
ratio of the methylated to the sum of methylated
and unmethylated intensities. All samples suc-
cessfully passed quality control (they had ≥75%
probes with a detection p-value ≤5 × 10−5).
Probes were filtered out based on the following
criteria: 1) probes with ≤75% samples showing
detection p-values ≤0.01; 2) probes located on
the sex chromosomes; 3) probes not targeting
CpG sites; 4) probes with common polymorph-
isms (MAF > 5% in European population). After
filtering, 765,396 probes remained. Batch effects
were corrected using the ComBat function [75].
Relative proportions of white blood cell types, i.
e. CD4+ and CD8 + T cells, monocytes (Mono),
granulocytes (Gran), B cells (Bcell) and natural
killer (NK) cells, were calculated using the
Houseman algorithm [76]. These proportions
were included in linear regression models prior
analyses. As analyses were based on both base-
line and follow-up, only CpG-sites present on
both chips were analysed. The expanded annota-
tion table by Price et al. was used for CpG site
annotation [77], defining for each CpG site the
associated gene and distance to the closest tran-
scriptional start site (TSS). With the exception of
miRNA genes, only probes that were within
2,000 base pairs down/upstream of the TSS of
genes were taken into consideration, based on
the assumption that DNA methylation and gene
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expression are closely related within this region
[78]. The two methylation data sets, i.e. at base-
line and follow-up, were merged, resulting in
148,788 CpG sites to be analysed.
Genotyping and imputation
All study participants at baseline (n = 786) were
genotyped using the Infinium Global Screening
Array at the SNP&SEQ SciLife Platform at
Uppsala University, interrogating a total of
700,078 genetic variants. Prior imputation, quality
control steps were performed using Plink 1.9 [79]
as following: samples were excluded based on gen-
otyping call rate (<95%), high heterozygosity >2
standard deviations (SD) and missingness rate
>0.05 (n = 21 samples); probes were removed
based on the minor allele frequency (MAF)
(<1%), Hardy-Weinberg equilibrium (HWE)
(<1e-6) and missing rate (>5%) (n = 203,774
probes). A total of 496,304 genotypes of 765 indi-
viduals were included in the pre-phasing approach
implemented in SHAPEIT version 2.7 (r904) [80]
and then imputed using IMPUTE2 software (ver-
sion 2.3.2) [81], taking the 1000 Genome Project
phase 3 integrated variant set as a reference
(release October 2014). Data were further filtered
using HWE cut-off of 0.01, imputation info score
>0.3 and MAF >0.01. A cis analysis was performed
for the 74 participants at follow-up who had mea-
sured both methylation and genetic data.
Common single nucleotide polymorphisms
(SNPs) within ±100kbp of the differentially methy-
lated CpG site position in Human Reference
Genome build 37 (hg19) were investigated with
the genome browser [82].
Replication dataset
We interrogated an already pre-processed, pub-
lically available dataset of 58 post-mortem corti-
cal tissues from MDD-diagnosed individuals (n
= 29) and 29 matched controls [83]. In these
samples, neuronal and glia cell proportions were
determined by fluorescence-activated cell sorting
(FACS). Methylation levels were separately mea-
sured in both cell types using Illumina 450K
methylation Beadchip determining 480,492
methylation sites. The two methylation datasets
are available under the GEO accession number
GSE41826. To avoid confounding of methylation
signal by ethnicity, only data from Caucasian
individuals were included in further analyses (n
= 45).
Methylation-expression dataset
To integrate the methylome with the transcrip-
tome, a third independent open-access dataset (E-
GEOD-56,047) was used, containing both tran-
scriptome and methylome data from CD14+ sam-
ples derived from 1,202 participants (44–83
years-old) [84]. The current cohort is part of a
larger study that investigated cardiovascular dis-
eases in a cohort of Caucasians, African
Americans and Hispanics [85]. The deposited
data contained information about age, race/eth-
nicity, study site, sex, methylation/expression
chip, B-cells, T-cells, neutrophils and natural
killer cell proportions. For the purpose of our
analyses, methylation data were filtered for out-
liers based on a graphical boxplot (n = 22 outliers
removed). Methylomes were profiled with the
Illumina 450K methylation Beadchip and tran-
scriptomes were measured with the Illumina
HumanHT-12 V4.0 expression Beadchip. Details
about methylation data pre-processing and tran-
scriptomic quality control can be found else-
where [84].
Expression cohort
Gene expression profiles in the dentate gyrus and
CA1 subregions of the hippocampus were analysed
in 15 patients diagnosed with MDD and 15 age-,
sex- and race-matched controls using data from a
publically available case/control study
(ArrayExpress accession E-GEOD-24,095). Data
were analysed using the cDNA hybridization to
48K human HEEBO whole-genome microarrays.
Average expression values for all hybridizations
were available for each individual [86]. Data were
normalized using linear-Log normalization to sta-
bilize the variance of low expressing genes, and
then spatial plus intensity based LOWESS to
remove spatial and intensity related biases, using
the MAANOVA library [86].
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Evaluation of genomic sites in brain and blood
The functional relevance of the differentially methy-
lated DNA sites was further investigated in blood and
brain, using chromatin state analysis [87] and
Spearman correlations [63]. Based on the availability
of chromatin state data as predicted with Hidden
Markov Models (HMMs), seven brain tissues were
analysed: brain angular gyrus (BrainAG), brain ante-
rior caudate (BrainAC), brain cingulate gyrus
(BrainCG), brain hippocampus (BrainHIPPO), brain
inferior temporal lobe (BrainITL), brain substantia
nigra (BrainSN), brain dorsolateral prefrontal cortex
(BrainDLPC) and peripheral blood mononuclear pri-
mary cells (PBMC). Data were loaded from Roadmap
Epigenomics Project of 37/hg19 version of human
genome in WashU Epigenome Browser http://epigen
omegateway.wustl.edu/legacy/. For easier visualiza-
tion, the 18-state model for the production of the
segmentations according to the gene regulatory role
was reduced to five regions, i.e. active/flanking active/
bivalent/poised transcription start site (TSS), active/
bivalent/genic enhancer, flanking bivalent TSS/
enhancer, active transcription and repressed
polyComb state. We used Spearman correlations to
assess DNA methylation correspondence between
blood and three brain regions, i.e. Brodmann area
(BA) 10 (prefrontal cortex), BA20 (temporal cortex)
and BA7 (parietal cortex), using the online BECon
tool https://redgar598.shinyapps.io/BECon/ [63]. The
cohort consisted ofmethylation data of 16 individuals.
More details about the preprocessing of this DNA
methylation dataset are available in [63]. The tran-
scription levels in different brain tissues and whole
blood of the associated genes to the differentially
methylated CpGs were investigated using GTEx
https://gtexportal.org/home/ [88]. Moreover, using a
population sample in the GTEx Consortium, geno-
types at genetic loci were included in linear regression
models and the significance to the gene expression
was measured [88]. Thus, the identified genetic var-
iants in the mQTL analysis were classified as eQTLs if
they showed contribution to the gene expression
using the quantitative trait loci (eQTL) mapping.
Statistical analysis
We investigated genome-wide methylation differ-
ences with depression risk in the discovery cohort
of n = 59 adolescents, using a longitudinal
approach. All statistical analyses were performed
in R version 3.4.1. In order to reduce the
unwanted variability in DNAm caused by intrinsic
(age, sex) and environmental (baseline depression,
batch effect) factors, DNAm profiles were first
regressed against baseline depression DAWBA
scores, age, sex and batch. The resulting residuals
were then included as covariates in the following
linear regression model: methylationfollow-up ~ resi-
dualsbaseline + depression-transformed variablefol-
low-up + agefollow-up + sex. The inflation factor
lambda was calculated for the linear models at
follow-up, by dividing the median of chi-squared
test statistics with the expected median of chi-
squared distribution. In the next step, methylation
M-values at the most significant DNA loci were
also regressed against the SUAS scores in linear
regression models, adjusting for sex and age at
follow-up. Unadjusted (raw) p-values <10−4 were
considered significant.
In replication analyses using data from brain
tissue, methylation levels of significant CpG sites
from the discovery analysis were regressed against
the yes/no depression diagnosis, adjusting for age
and sex. Analyses were run separately for neurons
and glia cells and FDR adjustment was applied to
the raw p-values. Associations between methyla-
tion and RNA expression levels at the identified
genes were tested in an independent cohort.
Methylation data were firstly regressed against
age, race, study site, gender, methylation chip
and the sample contamination with non-targeted
cells, i.e. non-monocytes. The resulting residuals
were included in linear regression models as an
independent variable, together with expression
values as dependent variables. Covariates were
age, race, study site, gender, expression chip and
the sample contamination with non-targeted cells.
Given that expression data was obtained as nor-
malized log2 ratio representing MDD/control
mRNA expression, quantitative analysis could not
be performed. Expression data were analysed using
a two-sided binomial test, assuming a 0.5 prob-
ability threshold.
Given the relatively small sample size (n = 72)
having both genotype and methylation data in the
discovery cohort, only SNPs in no linkage disequi-
librium (r^2 < 0.8) and with MAF >0.3 were
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analysed. Linkage disequilibrium was calculated
using LDlink web-tool [89] and Haploview [90].
The genotypes were coded as ‘0ʹ (wild-type indi-
viduals), ‘1ʹ (heterozygous of minor allele) and ‘2ʹ
(homozygous of minor allele). The modulatory
effect of genetic sequence variant was shown on
the surrounding methylation levels [32].
Methylation quantitative trait locus analysis
(mQTL) was performed using likelihood ratio
tests, adjusted for age and sex. The p-value of the
SNP effect was calculated from the Chi-square
distribution with 1 degree of freedom.
Pyrosequencing
Methylation levels at cg24627299 the CpG sites show-
ing the highest DNA methylation difference were
experimentally measured using pyrosequencing at
baseline and follow-up. Out of the 786 adolescents
recruited at the baseline, a subset of 203 was fol-
lowed-up and had available extracted DNA. A total
of 44 individuals were defined as ‘cases’ based on the
DAWBA depression band ≥3 andMADRS-S scores ≥
9 and 159 as ‘controls’. Primers were designed using
PyroMark Design software (Qiagen) (Fwd:
ATGATTGAATAATTGGTATGAGAGT, 5´-bioti-
nylated Rev: AATTTAACCCTAAAAAAACTT
CCATTT, sequencing: TTAATATAATTATTTTT
AATAGAGT). Genomic DNA (500 ng) was bisul-
phite (BS)-converted using DNA methylation-Gold
Bisulphite Kit (Zymo Research) and eluted in 25 µl
of elution buffer. BS-DNA (~15 ng) was applied as a
template in the PCR performed with the PyroMarks
PCR kit (Qiagen) following manufacturer’s recom-
mendations. To verify the efficiency and sensitivity
of the PCR-pyrosequencing, we used Epitect
unmethylated and methylated human BS-DNA sam-
ples (Qiagen) as controls. The entire PCR product, 4
pmol of the sequencing primer, and streptavidin
sepharose high-performance beads (GR Healthcare)
were used for pyrosequencing on the PSQ 96 system
and PyroMark Gold 96 reagent kit (Qiagen). The
PyroMark CpG software 1.0.11 (Qiagen) served for
generating methylation levels. Technical covariates, i.
e. bisulphite conversion batch, pyrosequencing plate
and date of the pyrosequencing analysis were tested
against methylation values, separately at baseline and
follow-up. Methylation levels at baseline were firstly
regressed against age, sex and technical covariates, and
the resulting residuals were included in linear regres-
sion models at the follow-up. The following model
was applied for the measured methylation levels at
follow-up: methylation follow-up ~ residuals baseline
+ depression-transformed variable follow-up (0/1) +
age follow-up + sex + technical covariates.
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